Thera-SAbDab

NECITUMUMAB

>   Structural Summary
TherapeuticNecitumumab
TargetEGFR
Heavy ChainQVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSS
Light ChainEIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIK
100% seqID Fv Structure3b2u [Fvs: CD, FG, HL, JK, NO, QR, TU, WX], 3b2v [Fvs: HL], 6b3s [Fvs: CD, FG, HL, JK]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2008
INN Year Recommended2009
Companies InvolvedImClone Systems, Eli Lilly
Conditions ApprovedNon-small cell lung cancer
Conditions ActiveSolid tumours
Conditions DiscontinuedColorectal cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]